Olanzapine serum concentrations in psychiatric patients given standard doses: The influence of comedication

Therapeutic Drug Monitoring

Volumn 21, Issue 1, 1999, Pages 87-90

  Olesen, Ole V ^a   Linnet, Kristian ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Comedication; Olanzapine; Psychiatric patients; Serum concentration

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROTHIXENE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 INHIBITOR; DISULFIRAM; LEVOMEPROMAZINE; NORTRIPTYLINE; OLANZAPINE; ORPHENADRINE; OXYTETRACYCLINE; PERPHENAZINE; SERTRALINE; VALPROIC ACID; ZUCLOPENTHIXOL;

ADOLESCENT; ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; SEDATION; STEADY STATE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUG MONITORING; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; PSYCHOTIC DISORDERS;

EID: 0033055756     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199902000-00013     Document Type: Article

References (18)

1. Beasley CM Jr, Hamilton SH, Crawford AM et al. Olanzapine versus haloperidol: Acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-37.
2. Casey DE. The relationship of pharmacology to side effects. J Clin Psychiatry 1997;58:55-62.
3. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997;58:45-49.
4. Kassahun K, Mattiuz E, Nyhart E Jr, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;:81-93.
5. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;27:658-66.
6. Dellva MA, Tran P, Tollefson GD, et al. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997;48:1571-7.
7. Tran PV, Hamilton SH, Kuntz AJ, et, al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17: 407-18.
8. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 1997;17:472-7.
9. Ereshefsky L. Pharmacokinetics and drug interactions: Update for new antipsychotics. J Clin Psychiatry 1996;57:12-25.
10. Gram LF, Overo KF. Drug interaction: Inhibitory effect of neuroleptics on metabolism of tricyclic antidepressants in man. Br Med J 1972;17:463-5.
11. Overo KF, Gram LF, Hansen V. Interaction of perphenazine with kinetics of nortriptyline. Acta Pharmacol Toxicol 1977;40:97-105.
12. Jerling M, Bertilsson L, Sjoqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: An example with amitriptyline and nortriptyline. Ther Drug Monit 1994;16:1-12.
13. Jerling M, Dahl ML, Aberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996;59:423-8.
14. Linnet K. Comparison of the kinetic interactions of the neuroleptics perphenazine and zuclopenthixol with tricyclic antidepressives. Ther Drug Monit 1995;17:308-11.
15. Jerling M, Lindstrom L, Bondesson U, et al. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: Evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
16. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996;31:198-214.
17. Olesen, OV, Linnet K. Determination of olanzapine in serum by high performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotic drugs. J Chromatogr 1998;714:309-15.
18. Tugnait M, Hawes EM, McKay G, et al. N-oxygenation of clozapine by flavin-containing monooxygenase. Drug Metab Dispos 1997;25:524-7.